Adjuvant therapy with Imfinzi (durvalumab) and Imjudo (tremelimumab-actl) in patients with resected renal cell carcinoma was ...

Induction Yervoy (ipilimumab) plus Opdivo (nivolumab) followed by consolidative chemoradiotherapy demonstrated bladder ...

Active surveillance (“watch and wait”) functioned as a strategy to monitor biology while preserving sequencing flexibility for subsequent therapies. Living long-term with cancer means learning to live ...

Daiichi Sankyo announced that the first patient has been dosed in the global phase 3 TROPION-Lung17 trial. The study is evaluating DATROWAY in patients with locally advanced or metastatic nonsquamous ...

At 24 months overall survival was 62.8% with Welireg plus Lenvima versus 55.4% with Cabometyx. Median overall survival was 34 ...

Overall, day two of ASCO GU emphasized that advances in therapy must go hand-in-hand with patient-centered research. These ...

The third and final day of the 2026 American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium highlighted important developments in kidney cancer treatment, including combination ...

Longitudinal PRO modeling, rather than time-to-worsening censoring, indicated maintained HRQOL and pain outcomes with ...

The OriGAMI-4 trial reveals subcutaneous Rybrevant's 45% response rate in metastatic head and neck cancer patients after ...

Cancers Symposium, and the updates were full of hope for people with advanced prostate cancer. CURE highlights two studies ...

The bispecific ADC izalontamab brengitecan improved survival for patients with metastatic triple-negative breast cancer in a ...

Across the board, these experts emphasized that the 2026 ASCO GU Cancer Symposium will provide patients and clinicians with ...